Duodenal ulcer, gastric ulcers, erosive esophagitis, Zollinger-Ellison Syndrome, H. pylori eradication.
Proton Pump Inhibitor; Antiulcer
Lansoprazole is a substituted benzimidazole, and is also known as PPI due to its property to block the final step of acid secretion by inhibiting H+/K+ ATPase enzyme system in gastric parietal cell. Both basal and stimulated acid are inhibited.
Lansoprazole appears to be a selective inhibitor of the cytochrome P-450 monooxygenase system; there may be an effect on hepatic clearance, but there have been no reports to date of clinically relevant interactions. There is some uncertainty over the effect of Lansoprazole on the oral combined contraceptive pill. Further assessment is currently underway. Physiological changes similar to those found with Omeprazole are likely to take place because of the reduction in gastric acid, which is likely to influence the bacterial colonization of the stomach and duodenum and also vitamin B12 absorption.
Gastrointestinal disturbances, headache, dizziness, malaise, dry or sour mouth or throat.
USFDA Pregnancy category B.
.png&w=384&q=75)